Hub Services Market Analysis: U.S. Pharmaceutical Patient Support Programs | Rx Almanac
Comprehensive market sizing, competitive landscape, M&A activity, technology differentiation, and outlook for the U.S. pharmaceutical hub services market. Synthesized from multiple public market re...
Market Definition
Hub services are outsourced patient support programs operated by specialized third-party vendors on behalf of pharmaceutical manufacturers. They serve as the operational backbone connecting manufacturers, payers, pharmacies, and patients for specialty and high-cost therapies.
Sub-Segments
| Sub-Segment | Description |
|---|---|
| Enrollment / Intake | Patient and prescriber onboarding, consent capture, program registration |
| Benefit Verification (eBV) | Electronic verification of insurance coverage, formulary status, cost-sharing |
| Prior Authorization (ePA) | Submission, tracking, and appeals management |
| Financial Assistance / Copay | Copay card administration, PAPs, bridge/free goods, manufacturer savings programs |
| Pharmacy Coordination | Specialty pharmacy routing, dispensing coordination, limited distribution drug management |
| Adherence / Nurse Support | Clinical nurse educators, adherence monitoring, refill management |
| Buy-and-Bill Reimbursement | Support for provider-administered biologics: medical benefit verification, claims support, J-code management |
Scope Boundaries
In scope: Outsourced hub programs managed by third-party vendors; manufacturer-funded patient support; copay program administration fees; eBV/ePA technology platforms.
Out of scope: In-house pharma patient services teams; PBM-side formulary/UM; direct copay assistance spend ($23B+); specialty pharmacy dispensing revenue; clinical trial recruitment.
Market Size & Growth
Global Market
| Year | Consensus Estimate | Source |
|---|---|---|
| 2024 | $3.2—3.4B | Grand View Research |
| 2025E | $3.5—3.6B | Market.us |
| 2026E | $3.9—4.0B | Extrapolated at 10% CAGR |
| 2028E | $4.7—4.8B | Extrapolated at 10% CAGR |
U.S. Operator-Fee Revenue
| Year | Estimated U.S. Market | Growth |
|---|---|---|
| 2023 | ~$1.2—1.3B | — |
| 2024 | ~$1.4—1.6B | ~9—10% |
| 2025E | ~$1.5—1.8B | ~8—9% |
| 2026E | ~$1.6—1.9B | ~8—9% |
| 2028E | ~$2.0—2.3B | ~8—10% |
Derived from Grand View Research U.S. data ($1.227B in 2023, 8.2% CAGR to 2030) and Market.us North America estimate of $1.7B in 2025.
Note: The ConnectiveRx PE investors estimated TAM at $3.0—3.5B growing 7—9% CAGR as of 2022 (see ConnectiveRx Deep Dive). This likely represents a broader TAM definition blending operator fees with total program management economics. The original 7—9% CAGR estimate has proven slightly conservative; current consensus points to 8.2—10.8% CAGR through 2030—2033.
Sub-Segment Breakdown
| Segment | Revenue Share (2024) | CAGR | Key Dynamics |
|---|---|---|---|
| Program Enrollment / Hub Ops | ~31—33% (largest) | ~6.4% | Core call-center enrollment; mature but volume growing with specialty launches |
| Reimbursement / Affordability | ~20—22% | ~11—12% | Fastest growing; copay card admin, PAP enrollment; driven by accumulator/maximizer complexity |
| Treatment Navigators (PA Mgmt) | ~15—18% | ~10.4% | Second-fastest growth segment |
| Clinical Educator / Adherence | ~12—15% | ~8% | Growing with cell/gene therapies |
| Specialty Pharmacy Coordination | ~10—12% | ~9% | SP routing, order management |
| Data / Analytics / Other | ~8—10% | ~12% | Emerging: AI-driven analytics, RWE support |
Growth Drivers
-
Specialty drug pipeline (primary driver): Specialty spending reached $416.8B in U.S. in 2024 (51.7% of total Rx, +11.9% YoY). ~75% of 7,000+ drugs in development are specialty agents; 80+ rare disease drugs expected 2025—2027. Each launch typically requires a dedicated hub program.
-
GLP-1 explosion: Manufacturer transitional assistance covers >50% of commercial GLP-1 claims. CMS Medicare GLP-1 Bridge launching July 2026 at $245/month, creating an entirely new hub/access management channel.
-
Prior authorization burden: Medicare Advantage processed 52.8M PA requests in 2024 (up from 49.8M in 2023). 92% of medical practices have hired/reassigned staff solely for PA. 56% of new brand launch Rx attempts went unfilled in year one as of 2022 (up from 37% in 2016).
-
Biosimilar complexity: Record 18 new biosimilars approved in 2024; 40+ expected 2025—2027. Each launch creates competitive program layering (originator vs. biosimilar access programs).
-
Copay accumulator/maximizer dynamics: Manufacturers spent $23B on copay assistance in 2023. PBMs/plan sponsors now capture ~$6.5B through accumulator/maximizer programs (40%+ of commercially insured lives). This adversarial dynamic drives demand for sophisticated hub-side financial navigation.
Competitive Tiers
Tier 1: Full-Stack / Largest
Offer hub services integrated with specialty pharmacy, drug distribution, broader commercialization, or massive provider/payer networks. Compete on breadth, infrastructure scale, and vertical integration.
| Company | Ownership | Differentiators |
|---|---|---|
| EVERSANA | Private (Water Street / JLL; merged with Waltz Health Aug 2025; ~$6B combined) | ACTICS eBV/ePA; 6,000+ employees; 650+ clients; unique pharma-to-payer connectivity post-Waltz |
| Cencora / Lash Group | Public (NYSE: COR) | 30-year hub leader; 100+ programs, 15M+ patients; direct distribution data access |
| McKesson / CoverMyMeds | Public (NYSE: MCK) | 350+ EHR integrations, 950K+ providers; ~90% of U.S. ePA volume; acquired RxLightning and FastAuth (2025) |
| Cardinal Health / Sonexus | Public (NYSE: CAH) | ConnectSource platform; AI-powered 24/7 patient chat; speech analytics |
| Valeris (PharmaCord + Mercalis) | PE (Permira; formed May 2025) | “Largest independent patient access company”; 2,900+ employees; 500+ clients |
| Optum | Public (NYSE: UNH) | 127M+ members; OptumRx Savings IQ saved $1.3B in 2024. PBM affiliation limits manufacturer adoption. |
| IQVIA | Public (NYSE: IQV) | 15 of top 20 pharma clients; unmatched real-world data; hub + pharmacovigilance |
Tier 2: Independent Specialists
Focused primarily on hub services with deep expertise and strong tech platforms. Mostly PE-backed and actively building.
| Company | Ownership | Differentiators |
|---|---|---|
| ConnectiveRx | PE (Genstar majority; Harvest/Blackstone minority); ~1,400 employees | 2B Rx transactions/year; 90M patients/year; Careform noncommercial pharmacy; launched DTP dispensing Sept 2025 |
| AssistRx | PE (WCAS since Feb 2024; ~$600M est.); ~430 employees | CoAssist reduced time-to-therapy from 12.2 to 3.7 days; acquired AllazoHealth AI (Apr 2025); 61K+ pharmacy network |
| Inizio Engage | PE (CD&R) | Trak360 platform; 96% first-call resolution; 35+ therapy areas; 25+ year rare disease heritage |
| CareTria | PE (Frazier since Feb 2025) | eBlu real-time BV/ePA (acquired Jul 2025); integrated SP + DTP + 3PL; rebranded Jan 2026 |
| CareMetx | PE (General Atlantic / Vistria); 600+ employees | ”Digital Hub”; 2M patients/year; 80+ brands; OutcomeRx value-based contracting |
| Phil | VC-backed | PHIL Direct platform (Sept 2025); 80—90% digital enrollment rates; GLP-1 focus |
| Conduent | Public (NASDAQ: CNDT) | IntelliHealth; 15 of top 20 pharma clients; 50% routine task automation |
Tier 3: Emerging / Niche
Newer entrants, technology-first disruptors, or narrow-focus specialists targeting specific therapeutic areas or operating paradigms.
| Company | Key Positioning | Differentiators |
|---|---|---|
| Neon Health | AI-native hub; workforce automation-first | Claims 2x faster, 80% cheaper; 98% call automation; $6M seed (Feb 2026) |
| eMAX Health | Software licensing for hybrid/insourced hubs | ResponseRx; enables manufacturers to run hub tech in-house |
| Momentum Life Sciences | Clinical Nurse Educator specialist | One Voice adherence platform; 67% abandonment reduction |
| ConnectMed360 | Rare/oncology/orphan specialist | National non-commercial pharmacy (50-state); white-glove ultra-rare programs |
| Claritas Rx | Predictive analytics for hub optimization | 80% discontinuation prediction accuracy; 95% abandonment forecasting; 80% PA denial prediction |
| RareMed Solutions | Rare/orphan disease dedicated hub | RarePath Connect portal; ultra-orphan specialization |
M&A Activity
Major Transactions (2020—2026)
| Year | Target | Acquirer/Investor | Type |
|---|---|---|---|
| 2020 | ConnectiveRx (recap) | Genstar + Harvest/Blackstone | PE recapitalization |
| 2021 | CareMetx | General Atlantic (majority) + Vistria (minority) | Growth equity recap |
| 2021 | Intouch Group | EVERSANA | Add-on (~$950M+) |
| 2022 | EVERSANA continuation fund | Water Street / JLL | $1.75B committed |
| 2024 (Feb) | AssistRx | WCAS | PE acquisition (~$600M est.) |
| 2024 (Sept) | PharmaCord | Permira | PE acquisition |
| 2025 (Feb) | Knipper Health | Frazier Healthcare | PE acquisition |
| 2025 (Mar—May) | Mercalis + PharmaCord —> Valeris | Permira (majority) | Platform merger |
| 2025 (Apr) | AllazoHealth assets | AssistRx (WCAS) | Add-on |
| 2025 (Jul) | eBlu Solutions | Knipper Health (Frazier) | Add-on |
| 2025 (Aug) | EVERSANA + Waltz Health | Water Street/JLL + GV | Platform merger (~$6B combined) |
| 2025 (Sept) | ConnectiveRx Pharmacy launch | Genstar | Organic vertical extension into DTP dispensing |
PE Platforms Building in Hub Services
| PE Firm | Platform | Strategy |
|---|---|---|
| Genstar Capital | ConnectiveRx | Hub + adherence + awareness; Careform + TMG acquisitions; added DTP pharmacy |
| Water Street / JLL | EVERSANA | Full-stack commercialization; 15+ acquisitions; Waltz Health merger (~$6B) |
| General Atlantic + Vistria | CareMetx | Digital hub transformation; PX Technology + Human Care Systems add-ons |
| Frazier Healthcare | CareTria | Buy-and-build: Knipper + eBlu; therapy initiation platform |
| WCAS | AssistRx | EHR-native enrollment; AllazoHealth AI add-on |
| Permira | Valeris | PharmaCord + Mercalis merger; “largest independent patient access company” |
| CD&R | Inizio Engage | Ashfield + Huntsworth transformation; clinical/nurse hub model |
Vertical Integration by Distributors
Big Three distributors have spent $16B+ on healthcare services/provider acquisitions since 2011:
- Cencora: Lash Group (2014), TheraCom ($250M, 2011), PharmaLex (1.28B EUR, 2022), OneOncology (~$5B, 2025)
- McKesson: CoverMyMeds ($1.1—1.4B, 2017), RxCrossroads ($735M, 2017), RxLightning, FastAuth
- Cardinal Health: Sonexus (2014), Specialty Networks ($1.2B, 2024), GI Alliance (~$2.8B, 2024)
Why PE Loves This Space
- Recurring revenue with high switching costs: Multi-year contracts tied to specific drug brands; switching risk estimated at 5—10% of brand revenue
- Specialty drug tailwinds: Every new specialty/rare-disease approval drives incremental hub demand; 500+ NME launches expected through 2030
- Fragmented, consolidatable market: Dozens of sub-scale providers as of 2020—2022 — classic roll-up opportunity
- Technology upgrade cycle driving margin expansion: Digital enrollment, ePA, and AI automation replacing headcount-heavy models
- Data network effects: Hub platforms sit on rich patient adherence, payer coverage, prescriber behavior, and dispensing data — increasingly monetizable
Deal Multiples
No hub-specific EBITDA multiples publicly disclosed. Comparable healthcare services technology transactions: 7x—15x EBITDA and 2x—6x revenue. Platform transactions with recurring revenue and tech differentiation command 12x—16x EBITDA.
Technology Differentiation
eBV/ePA Capabilities
| Platform | Network Scale | Key Capability |
|---|---|---|
| CoverMyMeds (McKesson) | 350+ EHRs, 50K+ pharmacies, 950K+ providers, 94% Rx volume | 62% of ePA determined in <2 hours; 3x faster than manual |
| Surescripts Touchless PA | 76K+ prescribers, 70+ medications | 22-second median approval; fully automated |
| Eversana ACTICS | 1,500+ payers, 90% U.S. covered lives | Real-time eBV + ePA integrated with hub workflow |
| Agadia PromptPA | 45+ health plans/PBMs, ~100M lives | Direct payer connections for specialty medications |
Eversana 90% eBV claim assessment: Contextually accurate — refers to electronic payer connectivity coverage (1,500+ payers, 90% of U.S. covered lives). The “43% baseline” represents older algorithm-based tools, not other electronic platforms. No independent audit exists. Not directly comparable to CoverMyMeds’ ~90% ePA volume share.
AI / Automation
AI investment in prior authorization grew 10x YoY, from $10M (2024) to $100M (2025). Key applications:
- Enrollment automation: AssistRx CoAssist reduced time-to-therapy 70% (12.2 to 3.7 days). CoverMyMeds e-enrollment processes 4 days faster than traditional hubs.
- PA decisioning: Surescripts Touchless PA delivers 22-second approvals. Availity AuthAI provides PA recommendations in <90 seconds.
- Adherence prediction: Claritas Rx achieves 80% therapy discontinuation prediction, 80% PA denial prediction, 95% abandonment forecasting.
- Call center NLP: Intent recognition, auto-STT, sentiment analysis, OCR for faxed forms. Conduent IntelliHealth automates 50% of routine agent tasks.
- AI-powered PSP outcomes: Industry data suggests 30—35% better patient outcomes vs. standard care and 30—40% reduction in operational costs.
Digital Hub Models
| Model | Description | Examples |
|---|---|---|
| Full-Service Digital Hub | End-to-end: BI/BV, ePA, copay, adherence, nursing, analytics | CareMetx, Lash Group, EVERSANA |
| Hub-Lite | Intake + light BV + routing to SP | Smaller programs, post-LOE brands |
| DTP / Digital-First | Consumer-facing app: Rx + telehealth + fulfillment | Phil (PHIL Direct), AssistRx Gateway |
| Hybrid / Dedicated | Manufacturer insources tech; outsources staffing | eMAX Health software licensing model |
CMS ePA Mandate (January 2027)
FHIR-based APIs for payer PA standardized across all Medicare/Medicaid payers. Hub vendors with early FHIR compliance (CoverMyMeds, Surescripts ecosystem) hold integration advantage. EHR-embedded workflows are becoming table stakes.
Win/Loss Dynamics
Vendor Selection Criteria
Based on 2024 CareMetx Patient Services Report (survey of market access leaders):
| Priority | Criterion | Est. Weight |
|---|---|---|
| 1 | Comprehensive suite of patient services solutions | ~25% |
| 2 | Strong understanding of patient journey alignment | ~20% |
| 3 | Flexible/customizable service offering | ~15% |
| 4 | Demonstrated performance metrics / evidence of results | ~15% |
| 5 | Technology — enrollment automation and EHR integration | ~15% |
| — | Therapeutic area expertise, data transparency, cost | ~10% combined |
Switching Drivers
| Reason | Frequency | Details |
|---|---|---|
| Poor data transparency / “black box” | Most common | Hubs providing quarterly summaries while keeping insights locked; driving pharma to insource technology |
| Technology inadequacy | Increasing | Failure to offer digital enrollment, EHR integration, real-time eBV/ePA |
| Underperformance on speed-to-therapy | Common | Missing time-to-first-fill KPIs triggers formal review |
| Data ownership disputes | Emerging | Manufacturer demands for data portability that incumbent resists |
| M&A / Strategic realignment | Periodic | Consolidation activity forces program re-evaluation |
Switching inhibitors: Revenue risk during transition estimated at 5—10% of brand revenue. New hub onboarding requires 90—180+ days for complex programs. Manufacturers spend >$5B annually on patient access programs — switching represents significant operational risk.
Contract Structure
- Initial term: 3 years (standard full-service hub)
- Renewals: 1-year by mutual agreement; some evergreen
- Pricing models: Transactional (per-BV, per-PA, per-call), FTE-based, Hybrid (FTE base + transactional), PPPM ($75—200/patient/month for adherence), Value/outcomes-based (tied to fill rates, adherence)
- Hub-lite/transactional: 1—2 year terms with easier exit
Decision-Makers
Market access leads serve as primary decision-maker ~1/3 of the time, with cross-functional influence from commercial ops, patient services, brand/marketing, procurement, and medical affairs. External consultants (Blue Fin Group, Protean, TwoLabs) frequently engaged for vendor selection.
Benchmarks
Hub Program Cost Ranges
| Program Size | FTE Count | Est. Annual Cost |
|---|---|---|
| Small / Rare Disease | <10 FTEs | $2M—$8M/year |
| Medium | 10—50 FTEs | $8M—$30M/year |
| Large / Pooled | 50+ FTEs | $30M—$100M+/year |
| Cell/Gene Therapy | Variable | $5M—$15M+ |
Total manufacturer investment in patient access programs exceeds $5B annually.
Time from Enrollment to First Fill
| Setting / Method | Time to First Fill | Source |
|---|---|---|
| Overall average (85 specialty brands) | 29 days | BrightInsight/Claritas Rx |
| Life-threatening conditions | ~14—15 days | BrightInsight/Claritas Rx |
| Non-life-threatening conditions | ~40—45 days | BrightInsight/Claritas Rx |
| Integrated health-system SP | 6 days median | JMCP |
| External SP transfer | 13 days median | JMCP |
| CoverMyMeds ePA (specialty) | 1.5 days (vs. 17 days manual) | CoverMyMeds |
| AssistRx CoAssist digital enrollment | 3.7 days (vs. 12.2 days traditional) | AssistRx/WCAS |
PA First-Pass Approval Rates
| Population | First-Pass Approval |
|---|---|
| General (all physicians, all drugs) | 72% |
| Oncology, commercial (same-day) | ~10% |
| Oncology, Medicare (same-day) | ~23% |
| Specialty pharmacy-managed PA | 96% (vs. 76% at physician office) |
Important: IQVIA oncology data shows 10—23% same-day approval, but most initially rejected prescriptions are ultimately approved — 57% of commercially rejected patients filled within one year.
Enrollment-to-Fill Conversion
| Metric | Rate |
|---|---|
| Overall paid fill rate (85 specialty brands) | 62% |
| Life-threatening conditions | 70%+ |
| Non-life-threatening conditions | 40—50% |
| Illustrative hub funnel: enrolled —> dispensed | 47% |
| Novel specialty medicines | <50% filled |
Patient Abandonment by Stage (Immunology Study)
| Stage | Share of Total Abandonment |
|---|---|
| Enrollment | 6% |
| Funding Support | 24% |
| Coverage / PA | 58% |
| Operations / Fulfillment | Remainder |
Abandonment by out-of-pocket cost: $0—50 copay: 1.3—10%; $100+: 32—75%; >$350: >75%. With manufacturer copay support, commercial abandonment drops from 22% to 7%; Medicare from 49% to 5%.
Call Center Metrics
| Metric | Benchmark |
|---|---|
| Average Handle Time | 6.6 min (healthcare avg); hub calls likely higher |
| First Call Resolution | 52% (healthcare avg); 70—79% target; Inizio claims 96% |
| Call Abandonment Rate | 7% (healthcare); 4.23% (specialty pharmacy) |
| Average Speed of Answer | 3 min 22 sec (healthcare) |
| Cost per Call | ~$4.90 |
Outlook
Growth Catalysts (2025—2028)
- Specialty drug pipeline acceleration: 80+ rare disease drugs through 2027; cell/gene therapies ($3.5M+ per dose) each requiring dedicated hub infrastructure
- GLP-1 access expansion: CMS Medicare Bridge (July 2026); expanding indications (CV, renal, sleep apnea, Alzheimer’s) multiplying program scope
- CMS ePA mandate (January 2027): FHIR-based standardized PA APIs reshape hub tech requirements; early compliance = competitive advantage
- AI-driven margin expansion: 30—40% cost reduction through enrollment/PA/call center automation while improving outcomes
- Biosimilar program layering: 40+ launches creating competitive complexity and duplicate hub demand
Key Risks
- In-sourcing by large pharma: Manufacturers “reclaiming control over patient experience” by insourcing hub technology while retaining outsourced staffing — compressing traditional hub vendor scope
- AI disruption of call center model: Neon Health claims 98% call automation at 80% lower cost. AI investment in PA alone grew 10x YoY to $100M. Traditional FTE-heavy operators face margin compression.
- Copay accumulator/maximizer expansion: PBMs capture ~$6.5B of manufacturer copay funds annually. If accumulators expand further, the $23B copay spending demand driver could face structural headwinds.
- Regulatory risk: Transparency mandates, potential federal accumulator regulation, and state-level copay reform could alter the financial assistance landscape
- PE concentration risk: Aggressive roll-ups could reduce competition/innovation. If platforms prioritize margin extraction over quality, buyers may accelerate insourcing.
- Cybersecurity: Cencora/Lash Group 2024 breach (1.43M individuals, $40M settlement) highlights PHI risk for hub operators
Predictions
- Market reaches $2.0—2.3B U.S. operator revenue by 2028
- AI-native entrants claim 5—10% market share by 2028, primarily at expense of mid-tier call-center-heavy incumbents
- 2—3 additional major PE transactions through 2027 (CareMetx, ConnectiveRx, Conduent as potential candidates)
- Distributor integration deepens: Cencora, McKesson, Cardinal Health continue building patient services as margin enhancement and distribution lock-in
- Hybrid hub models become standard: Binary outsourced vs. insourced dissolves — manufacturers own tech, outsource staffing/clinical
- Data monetization emerges: Hub operators commercialize analytics products, RWE packages, and predictive tools from longitudinal patient journey data
Cross-References
- Hub Services category page
- Hub Services Overview (concept)
- ConnectiveRx Deep Dive
- Eversana Patient Services Analysis
- Hub RFP Framework
Analysis compiled April 2026. All market size estimates based on publicly available research reports and should be treated as directional. Deal values marked as estimated or undisclosed reflect best available information from press releases, industry sources, and financial media. Hub-specific benchmarks (program costs, call center metrics) have limited public disclosure; figures synthesized from contextual data and adjacent market information.